Feline immunodeficiency virus is concentrated in milk early in lactation

被引:22
作者
Allison, RW [1 ]
Hoover, EA [1 ]
机构
[1] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA
关键词
D O I
10.1089/088922203763315759
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We studied mother-to-offspring transmission of feline immunodeficiency virus (FIV), focusing on milk-borne virus transmission in order to assess its similarities to perinatal HIV transmission. We also attempted to evaluate the influence of intragestational treatment with 9-[2-(phosphono-methoxy)-propyl] adenine (PMPA) on virus transmission to offspring. Eleven female cats (queens), chronically infected with FIV-B-2542 and bred to an FIV-negative male, produced a total of 25 viable and 18 nonviable term kittens. Overall, the vertical transmission rate by untreated queens was 22%, similar to that for HIV, which unfortunately precluded adequate assessment of PMPA efficacy. However, at delivery 9 of 10 queens (90%) had higher viral RNA loads in milk (4 X 10(4) to 4 X 10(8) viral copies/ml) than in plasma (5 X 10(3) to 2.5 X 10(6) viral copies/ml). Conversely, 10 of 11 queens (91%) had lower proviral loads in milk cells (0 to 10(2) proviral copies/mug DNA) than blood cells (10(2) to 10(4) proviral copies/mug DNA). Thus, FIV is concentrated in early milk despite relatively low proviral loads in milk cells, suggesting that virus may be actively secreted by the mammary gland for dissemination to offspring. FIV provides a model for the study of milk-borne lentivirus transmission and assessment of strategies to reduce postnatal HIV vertical transmission.
引用
收藏
页码:245 / 253
页数:9
相关论文
共 75 条
[61]   Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques [J].
Van Rompay, KKA ;
Marthas, ML ;
Lifson, JD ;
Berardi, CJ ;
Vasquez, GM ;
Agatep, E ;
Dehqanzada, ZA ;
Cundy, KC ;
Bischofberger, N ;
Pedersen, NC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (09) :761-773
[62]   Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection [J].
Van Rompay, KKA ;
Berardi, CJ ;
Aguirre, NL ;
Bischofberger, N ;
Lietman, PS ;
Pedersen, NC ;
Marthas, ML .
AIDS, 1998, 12 (09) :F79-F83
[63]   Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection [J].
Van Rompay, KKA ;
McChesney, MB ;
Aguirre, NL ;
Schmidt, KA ;
Bischofberger, N ;
Marthas, ML .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (04) :429-438
[64]   Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA [J].
Van Rompay, KKA ;
Miller, MD ;
Marthas, ML ;
Margot, NA ;
Dailey, PJ ;
Canfield, DR ;
Tarara, RP ;
Cherrington, JM ;
Aguirre, NL ;
Bischofberger, N ;
Pedersen, NC .
JOURNAL OF VIROLOGY, 2000, 74 (04) :1767-1774
[65]   INFECTIVE AND ANTIINFECTIVE PROPERTIES OF BREAST-MILK FROM HIV-1-INFECTED WOMEN [J].
VANDEPERRE, P ;
SIMONON, A ;
HITIMANA, DG ;
DABIS, F ;
MSELLATI, P ;
MUKAMABANO, B ;
BUTERA, JB ;
VANGOETHEM, C ;
KARITA, E ;
LEPAGE, P .
LANCET, 1993, 341 (8850) :914-918
[66]   9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques [J].
vanRompay, KKA ;
Cherrington, JM ;
Marthas, ML ;
Berardi, CJ ;
Mulato, AS ;
Spinner, A ;
Tarara, RP ;
Canfield, DR ;
Telm, S ;
Bischofberger, N ;
Pedersen, NC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2586-2591
[67]  
Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5
[68]   Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus [J].
Wade, NA ;
Birkhead, GS ;
Warren, BL ;
Charbonneau, TT ;
French, PT ;
Wang, L ;
Baum, JB ;
Tesoriero, JM ;
Savicki, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (20) :1409-1414
[69]  
Wahl S M, 1997, Oral Dis, V3 Suppl 1, pS64
[70]  
Wasik TJ, 1999, J IMMUNOL, V162, P4355